![Peter Svalander](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter Svalander
Corporate Officer/Principal bei University of Gothenburg
Aktive Positionen von Peter Svalander
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
University of Gothenburg | Corporate Officer/Principal | 02.06.2010 | - |
Karriereverlauf von Peter Svalander
Ehemalige bekannte Positionen von Peter Svalander
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Swedish Biotechnology AB | Präsident | - | - |
Avaris AB
![]() Avaris AB Miscellaneous Commercial ServicesCommercial Services Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities. | Direktor/Vorstandsmitglied | - | - |
Statistik
International
Schweden | 4 |
Operativ
Director/Board Member | 1 |
Corporate Officer/Principal | 1 |
President | 1 |
Sektoral
Commercial Services | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Avaris AB
![]() Avaris AB Miscellaneous Commercial ServicesCommercial Services Avaris was founded in 2001 by research teams at the Karolinska Institute and Karolinska Innovations AB. The company is based on four proprietary technology platforms within cell and gene therapy. Avaris drives the research development and commercialization of new therapies in close collaboration with the founders, research teams, and strategic partners. The company is well positioned in cell and gene therapy field for chronic infections, cancer and inherited diseases. Avaris vision is to become the number one supplier of individualized cell and gene therapy treatments in northern Europe. In order to reach this goal it is exploring possibilities to acquire, or in license cell therapy technologies that complement the in house growth. Avaris is also open to partnering possibilities. | Commercial Services |
Swedish Biotechnology AB |
- Börse
- Insiders
- Peter Svalander
- Erfahrung